Success Metrics

Clinical Success Rate
94.0%

Based on 171 completed trials

Completion Rate
94%(171/182)
Active Trials
9(4%)
Results Posted
38%(65 trials)
Terminated
11(5%)

Phase Distribution

Ph not_applicable
7
3%
Ph early_phase_1
3
1%
Ph phase_3
64
32%
Ph phase_4
51
25%
Ph phase_1
52
26%
Ph phase_2
6
3%

Phase Distribution

55

Early Stage

6

Mid Stage

115

Late Stage

Phase Distribution183 total trials
Early Phase 1First-in-human
3(1.6%)
Phase 1Safety & dosage
52(28.4%)
Phase 2Efficacy & side effects
6(3.3%)
Phase 3Large-scale testing
64(35.0%)
Phase 4Post-market surveillance
51(27.9%)
N/ANon-phased studies
7(3.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.4%

171 of 183 finished

Non-Completion Rate

6.6%

12 ended early

Currently Active

9

trials recruiting

Total Trials

202

all time

Status Distribution
Active(9)
Completed(171)
Terminated(12)
Other(10)

Detailed Status

Completed171
Terminated11
unknown10
Recruiting9
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
202
Active
9
Success Rate
94.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (1.6%)
Phase 152 (28.4%)
Phase 26 (3.3%)
Phase 364 (35.0%)
Phase 451 (27.9%)
N/A7 (3.8%)

Trials by Status

completed17185%
recruiting94%
terminated115%
unknown105%
withdrawn10%

Recent Activity

Clinical Trials (202)

Showing 20 of 202 trialsScroll for more
NCT07076199Phase 3

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Recruiting
NCT06547619Early Phase 1

Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM

Recruiting
NCT04880850Phase 3

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)

Completed
NCT04588259Phase 3

Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes

Completed
NCT04848480Phase 3

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)

Completed
NCT02546401Phase 3

Comparison of Insulin's Injection Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump

Completed
NCT05013229Phase 3

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

Completed
NCT04124302Phase 4

The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.

Completed
NCT07068295Phase 1

A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin Pump

Recruiting
NCT06809621Phase 1

A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump

Completed
NCT02462161Phase 1

Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart

Completed
NCT05946798Early Phase 1

Role of NADPH Oxidase in Microvascular Dysfunction Following GDM

Recruiting
NCT05946785Early Phase 1

Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes

Recruiting
NCT03987308Not Applicable

Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients

Recruiting
NCT04538352Phase 4

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

Completed
NCT06558708Phase 2

A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD

Recruiting
NCT04012138Phase 4

Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia

Recruiting
NCT03874715Phase 3

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Completed
NCT00447382Phase 3

Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes

Completed
NCT03660553Phase 4

Simplified Insulin Regimen for the Elderly

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
202